老年便秘病人肠道菌群对氧化三甲胺的影响及与心血管疾病关系的研究进展

doi:10.3969/j.issn.1003-9198.2024.12.024

摘要/Abstract

摘要： 便秘是老年群体最常见的消化系统疾病。研究发现,便秘与肠道菌群关系密切,老年便秘病人肠道菌群与健康人群存在显著差异,主要表现为双歧杆菌、乳酸杆菌、拟杆菌等有益菌丰度减少,而肠杆菌等有害菌丰度增加。肠杆菌增多、拟杆菌等有益菌减少可使氧化三甲胺(TMAO)生成增多,而TMAO是心血管疾病的独立危险因素,其生成增多可增加心血管疾病发病概率,因此,改善老年便秘或许可以减少心血管事件的发生。本综述从便秘与肠道菌群的关系、对TMAO的影响以及TMAO与心血管疾病的相关性三方面阐述了便秘、肠道菌群、TMAO以及心血管疾病之间的关系,以期为老年心血管疾病的防治提供新思路。

关键词: 便秘, 老年人, 肠道菌群, 氧化三甲胺, 心血管疾病

中图分类号:

R 442.2

王奕丹, 李春艳. 老年便秘病人肠道菌群对氧化三甲胺的影响及与心血管疾病关系的研究进展[J]. 实用老年医学, 2024, 38(12): 1297-1302.

参考文献

[1] United Nations. World Population Prospects: The 2017 Revision[EB/OL] (2017-07-21)[2024-02-03].Https://www.un.org/en/desa/World-Population-Prospects-2017-Revision.
[2] MUGIE S M, BENNINGA M A, DI LORENZO C. Epidemiology of constipation in children and adults: a systematic review[J]. Best Pract Res Clin Gastroenterol, 2011, 25(1):3-18.
[3] ANDY U U, VAUGHAN C P, BURGIO K L, et al. Shared risk factors for constipation, fecal incontinence, and combined symptoms in older U.S. adults[J]. J Am Geriatr Soc, 2016, 64(11):e183-e188.
[4] CHU H, ZHONG L, LI H, et al. Epidemiology characteristics of constipation for general population, pediatric population, and elderly population in China[J]. Gastroenterol Res Pract, 2014, 2014: 532734.
[5] 于阿莉,刘响,安莹莹,等.肠道菌群失调与慢性便秘的研究进展[J]. 国际消化病杂志,2017,37(2):83-86.
[6] ERHARDT R, HARNETT J E, STEELS E, et al. Functional constipation and the effect of prebiotics on the gut microbiota: a review[J]. Br J Nutr, 2023, 130(6):1015-1023.
[7] WANG Z, KLIPFELL E, BENNETT B J, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J]. Nature, 2011, 472 (7341): 57-63.
[8] CHANG J Y, LOCKE G R 3rd, MCNALLY M A, et al. Impact of functional gastrointestinal disorders on survival in the community[J]. Am J Gastroenterol, 2010, 105(4):822-832.
[9] 中华医学会老年医学分会,中华老年医学杂志编辑委员会. 老年人慢性便秘的评估与处理专家共识[J]. 中华老年医学杂志,2017,36(4):371-381.
[10] LI H, WANG K, HAO M, et al. The role of intestinal microecology in inflammatory bowel disease and colorectal cancer: a review[J]. Medicine: Baltimore, 2023,102(51):e36590.
[11] SCHNABL B, BRENNER D A.Interactions between the intestinal microbiome and liver diseases[J].Gastroenterology, 2014,146(6):1513-1524.
[12] JIN M, QIAN Z, YIN J, et al The role of intestinal microbiota in cardiovascular disease[J]. J Cell Mol Med, 2019, 23(4):2343-2350.
[13] LLOYD-PRICE J, ARZE C, ANANTHAKRISHNAN A N, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases[J]. Nature, 2019, 569(7758): 655-662.
[14] GROEN R N, DE CLERCQ N C, NIEUWDORP M, et al. Gut microbiota, metabolism and psychopathology: a critical review and novel perspectives[J]. Crit Rev Clin Lab Sci, 2018, 55(4):283-293.
[15] OHKUSA T, KOIDO S, NISHIKAWA Y, et al. Gut microbiota and chronic constipation: a review and update[J]. Front Med: Lausanne,2019,6:19.
[16] DIMIDI E, MARK SCOTT S, WHELAN K. Probiotics and constipation: mechanisms of action, evidence for effectiveness and utilisation by patients and healthcare professionals[J]. Proc Nutr Soc, 2020, 79(1):147-157.
[17] BERCIK P, COLLINS S M, VERDU E F. Microbes and the gut-brain axis[J]. Neurogastroenterol Motil, 2012, 24(5):405-413.
[18] DINAN T G, CRYAN J F. Gut-brain axis in 2016: brain-gut-microbiota axis-mood, metabolism and behaviour[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(2):69-70.
[19] 陈启仪,姜军.功能型便秘与脑-肠-菌群轴的关系[J].中华胃肠外科杂志,2017,20(12):1345-1347.
[20] BARBARA G, STANGHELLINI V, BRANDI G, et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease[J]. Am J Gastroenterol, 2005, 100(11): 2560-2568.
[21] ZHANG S, WANG R, LI D, et al. Role of gut microbiota in functional constipation[J]. Gastroenterol Rep: Oxf, 2021, 9(5):392-401.
[22] CANCELLO R, TURRONI S, RAMPELLI S, et al. Effect of short-term dietary intervention and probiotic mix supplementation on the gut microbiota of elderly obese women[J]. Nutrients, 2019, 11(12):3011.
[23] LIU X, XIE Z, SUN M, et al. Plasma trimethylamine N-oxide is associated with vulnerable plaque characteristics in CAD patients as assessed by optical coherence tomography[J]. Int J Cardiol, 2018, 265:18-23.
[24] HIIPPALA K, JOUHTEN H, RONKAINEN A, et al. The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation[J]. Nutrients, 2018, 10(8):988.
[25] CHATTERJEE S, PARK S, LOW K, et al. The degree of breath methane production in IBS correlates with the severity of constipation[J]. Am J Gastroenterol, 2007, 102 (4):837-841.
[26] GUO M, YAO J, YANG F, et al. The composition of intestinal microbiota and its association with functional constipation of the elderly patients[J]. Future Microbiol, 2020, 15:163-175.
[27] 李菁,邹晓平,王钟晗,等.老年慢性便秘患者肠道菌群结构特点的研究[J].胃肠病学,2021,26(5):274-278.
[28] 张旭,潘仁智,张晓玲,等.南京非便秘与便秘老人肠道菌群生态分布调查[J].南京中医药大学学报,2004,20(5):287-288.
[29] BIAGI E, NYLUND L, CANDELA M, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians[J]. PLoS One, 2010, 5(5): e10667.
[30] CLAESSON M J, CUSACK S, O′SULLIVAN O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly[J]. Proc Natl Acad Sci U S A, 2011, 108 (Suppl 1): 4586-4591.
[31] HAZEN S L, BROWN J M. Eggs as a dietary source for gut microbial production of trimethylamine-N-oxide[J]. Am J Clin Nutr, 2014, 100(3): 741-743.
[32] GRUPPEN E G, GARCIA E, CONNELLY M A, et al. TMAO is associated with mortality: impact of modestly impaired renal function[J]. Sci Rep, 2017, 7(1): 13781.
[33] AL-WAIZ M, MITCHELL S C, IDLE J R, et al. The metabolism of 14C-labelled trimethylamine and its N-oxide in man[J]. Xenobiotica, 1987, 17(5): 551-558.
[34] HEIANZA Y, MA W, DIDONATO J A, et al. Long-term changes in gut microbial metabolite trimethylamine N-oxide and coronary heart disease risk[J]. J Am Coll Cardiol, 2020, 75(7): 763-772.
[35] SHAN Z, SUN T, HUANG H, et al. Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes[J]. Am J Clin Nutr, 2017, 106(3):888-894.
[36] ZHANG W Q, WANG Y J, ZHANG A, et al. TMA/TMAO in hypertension: novel horizons and potential therapies[J]. J Cardiovasc Transl Res, 2021, 14(6): 1117-1124.
[37] BARREA L, ANNUNZIATA G, MUSCOGIURI G, et al. Trimethylamine-N-oxide (TMAO) as novel potential biomarker of early predictors of metabolic syndrome[J]. Nutrients, 2018, 10(12):1971.
[38] JANEIRO M H, RAMÍREZ M J, MILAGRO F I, et al.Implication of trimethy lamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target[J]. Nutrients, 2018, 10(10): 1398.
[39] WANG Z, ROBERTS A B, BUFFA J A, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis[J].Cell, 2015,163(7):1585-1595.
[40] KOETH R A, WANG Z, LEVISON B S, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis[J]. Nat Med, 2013, 19(5): 576-585.
[41] WANG Q J, SHEN Y E, WANG X, et al. Concomitant memantine and Lactobacillus plantarum treatment attenuates cognitive impairments in APP/PS1 mice[J]. Aging: Albany NY, 2020, 12(1): 628-649.
[42] FU B C,HULLAR M A J, RANDOLPH T W, et al. Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine with inflammatory and cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study[J]. Am J Clin Nutr, 2020, 111(6): 1226-1234.
[43] YOO W, ZIEBA J K, FOEGEDING N J, et al. High-fat diet-induced colonocyte dysfunction escalates microbiota-derived trimethylamine N-oxide[J]. Science, 2021, 373(6556): 813-818.
[44] KOETH R A, WANG Z, LEVISON B S, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis[J]. Nat Med, 2013, 19(5):576-585.
[45] CHEN K, ZHENG X, FENG M, et al. Gut microbiota-dependent metabolite trimethylamine N-oxide contributes to cardiac dysfunction in western diet-induced obese mice[J]. Front Physiol, 2017, 8: 139.
[46] ZHEN J, ZHOU Z, HE M, et al. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases[J]. Front Endocrinol: Lausanne, 2023, 14: 1085041.
[47] ZHU W, GREGORY J C, ORG E, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk[J]. Cell, 2016, 165(1): 111-124.
[48] DEAN Y E, ROUZAN S S, LOAYZA PINTADO J J, et al. Serum trimethylamine N-oxide levels among coronary artery disease and acute coronary syndrome patients: a systematic review and meta-analysis[J]. Ann Med Surg: Lond, 2023, 85(12): 6123-6133.
[49] MENTE A, CHALCRAFT K, AK H, et al.The relationship between trimethy lamine-N-oxide and prevalent cardiovascular disease in a multiethnic population living in Canada[J]. Can J Cardiol, 2015, 31(9):1189-1194.
[50] GUO F, ZHOU J, LI Z, et al. The association between trimethylamine N-oxide and its predecessors choline, L-carnitine, and betaine with coronary artery disease and artery stenosis[J]. Cardiol Res Pract, 2020, 2020: 5854919.
[51] SHENG Z, TAN Y, LIU C, et al. Relation of circulating trimethylamine N-oxide with coronary atherosclerotic burden in patients with ST-segment elevation myocardial infarction[J]. Am J Cardiol, 2019, 123(6):894-898.
[52] MATSUZAWA Y, NAKAHASHI H, KONISHI M,et al. Microbiota-derived trimethylamine N-oxide predicts cardiovascular risk after STEMI[J]. Sci Rep, 2019, 9(1):11647.
[53] QI J, YOU T, LI J, et al. Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies[J]. J Cell Mol Med, 2018, 22(1):185-194.
[54] LI N, ZHOU J, WANG Y, et al. Association between trimethylamine N-oxide and prognosis of patients with acute myocardial infarction and heart failure[J]. ESC Heart Fail, 2022, 9(6):3846-3857.
[55] DONG Z, ZHENG S, SHEN Z, et al. Trimethylamine N-oxide is associated with heart failure risk in patients with preserved ejection fraction[J]. Lab Med, 2021, 52(4):346-351.
[56] 韩嘉明,段豪亮,刘杏利,等. 血浆氧化三甲胺水平与心力衰竭患者预后关系的Meta分析[J]. 实用心脑肺血管病杂志,2023,31(5):89-95.
[57] SUN X, JIAO X, MA Y, et al. Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome[J]. Biochem Biophys Res Commun, 2016, 481(1/2): 63-70.
[58] SHIH D M, ZHU W, SCHUGAR R C, et al. Genetic deficiency of flavin-containing monooxygenase 3 (Fmo3) protects against thrombosis but has only a minor effect on plasma lipid levels-brief report[J]. Arterioscler Thromb Vasc Biol, 2019, 39(6): 1045-1054.
[59] YANG W, ZHANG S, ZHU J, et al. Gut microbe-derived metabolite trimethylamine N-oxide accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis[J]. J Mol Cell Cardiol, 2019, 134: 119-130.
[60] MEYER K A, SHEA J W. Dietary choline and betaine and risk of CVD: a systematic review and meta-analysis of prospective studies[J]. Nutrients, 2017, 9(7): 711.
[61] 刘冬雪.三甲胺N-氧化物与心血管疾病的研究进展[J].临床与病理杂志,2022,42(11):2821-2825.
[62] HSU C N, HOU C Y, CHAN J Y H, et al. Hypertension programmed by perinatal high-fat diet: effect of maternal gut microbiota-targeted therapy[J]. Nutrients, 2019, 11(12):2908.
[63] LIANG X, ZHANG Z, LV Y, et al. Reduction of intestinal trimethylamine by probiotics ameliorated lipid metabolic disorders associated with atherosclerosis[J]. Nutrition, 2020, 79/80:110941.
[64] 张再强,丁家望,汪心安.三甲胺-N-氧化物与心血管疾病研究进展[J].中国老年学杂志,2018,38(15):3807-3810.